Review Article
Microbiome and Asthma: What Have Experimental Models Already Taught Us?
Table 2
Models of asthma and microbiome.
| Mice strain/antigen | Microbial or exposure evaluation | Effect | Endpoint | References |
| C57BL/6/nonantigen | Germ-free mice | Increase | Airway resistance and eosinophils in airways | [67] |
| C57BL/6/OVA | Vancomycin to neonatal mice | Decrease | Bacterial diversity |
[69] | Increase | Inflammation in allergic asthma |
| BALB/c/OVA | Oral supplementation with Lactobacillus reuteri | Decrease | Allergic airway response | [70] |
| BALB/c/OVA | Oral supplementation with Bifidobacterium longum | Decrease | Inflammation in allergic asthma | [71] |
| BALB/c/OVA | Oral supplementation with Enterococcus faecalis FK-23 |
Suppression | Th17 immune response | [73] |
| BALB/c/HDM | Lactococcus lactis | Inhibition | Th2 response | [74] |
| BALB/c/OVA | Heat-shock protein X (HspX) purified from Mycobacterium tuberculosis |
Regulation | Th1 immune response | [75] |
| BALB/c/OVA | BCG | Decrease | Specific-IgE levels, eosinophil, neutrophil, and lymphocyte counts in BAL | [76] |
| BALB/c/OVA | BCG and interleukin-12 vaccination | Decrease | Allergic airway inflammation | [77] |
| BALB/c/OVA | Killed Streptococcus pneumoniae | Protection | Asthma | [78] |
|
|